Mariko Isshiki

Mariko Isshiki

Auto-generated profile, based on publicly available information

Mariko Isshiki

Department of Genetics, Albert Einstein College of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJames B Thissen
James B Thissen
MIMariko Isshiki
Mariko Isshiki
CJCrystal Jaing
Crystal Jaing
YNYoshiro Nagao
Yoshiro Nagao
DADayanara Lebron Aldea
Dayanara Lebron Aldea
TSTetsuya Sano
Tetsuya Sano
Kawasaki disease (KD), first identified in 1967, is a pediatric vasculitis of unknown etiology that has an increasing incidence in Japan and many other countries. KD can cause coronary artery aneurysms. Its epidemiological characteristics, such as seasonality and clinical picture of acute systemic inflammation with prodromal intestinal/respiratory symptoms, suggest an infectious etiology for KD. Interestingly, multiple host genotypes have been identified as predisposing factors for KD. To explore experimental methodology for identifying etiological agent(s) for KD and to optimize epidemiological study design (particularly the sample size) for future studies, we conducted a pilot study. For a 1-year period, we prospectively enrolled 11 patients with KD. To each KD patient, we assigned two control individuals (one with diarrhea and the other with respiratory infections), matched for age, sex, and season of diagnosis. During the acute phase of disease, we collected peripheral blood, nasopharyngeal aspirate, and feces. We also determined genotypes, to identify those that confer susceptibility to KD. There was no statistically significant difference in the frequency of the risk genotypes between KD patients and control subjects. We also used unbiased metagenomic sequencing to analyze these samples. Metagenomic sequencing and PCR detected torque teno virus 7 (TTV7) in two patients with KD (18%), but not in control subjects (P = 0.111). Sanger sequencing revealed that the TTV7 found in the two KD patients contained almost identical variants in nucleotide and identical changes in resulting amino acid, relative to the reference sequence. Additionally, we estimated the sample size that would be required to demonstrate a statistical correlation between TTV7 and KD. Future larger scale studies with carefully optimized metagenomic sequencing experiments and adequate sample size are warranted to further examine the association between KD and potential pathogens, including TTV7.

24 June 2025 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MIMariko Isshiki
Mariko Isshiki
AGAnthony J. Griffen
Anthony J. Griffen
PMPaul Meissner
Paul Meissner
PSPaulette Spencer
Paulette Spencer
MCMichael D. Cabana
Michael D. Cabana
SRSrilakshmi M. Raj
Srilakshmi M. Raj
The detection of founder pathogenic variants, those observed in high frequency only in a group of individuals with increased inter-relatedness, can help improve delivery of health care for that community. We identified 16 groups with shared ancestry, based on genomic segments that are shared through identity by descent (IBD), in New York City using the genomic data of 25,366 residents from the All Of Us Research Program and the Mount Sinai BioMe biobank. From these groups we defined 7 as founder populations, mostly communities currently under-represented in medical genomics research, such as Puerto Rican and Garifuna. The enrichment analysis of ClinVar pathogenic or likely pathogenic (P/LP) variants in each group identified 201 of these damaging variants across the seven founder populations. We confirmed disease-causing variants previously reported to occur at increased frequencies in Ashkenazi Jewish and Puerto Rican genetic ancestry groups, but most of the damaging variants identified have not been previously associated with any such founder populations, and most of these founder populations have not been described to have increased prevalence of the associated rare disease. Twenty-two of 47 variants meeting Tier 2 prenatal screening criteria (1/100 carrier frequency within these founder groups) have never previously been reported. We show how population structure studies can provide insights into rare diseases disproportionately affecting under-represented founder populations, delivering a health care benefit but also a potential source of stigmatization of these communities, who should be part of the decision-making about implementation into health care delivery.

22 September 2021 in BMC Ecology and Evolution
Verified
Journal Article
Open access
PDF file
MIMariko Isshiki
Mariko Isshiki
INIzumi Naka
Izumi Naka
RKRyosuke Kimura
Ryosuke Kimura
NNNao Nishida
Nao Nishida
TFTakuro Furusawa
Takuro Furusawa
JOJun Ohashi
Jun Ohashi
Background: Homo sapiens have experienced admixture many times in the last few thousand years. To examine how admixture affects local adaptation, we investigated genomes of modern Polynesians, who are shaped through admixture between Austronesian-speaking people from Southeast Asia (Asian-related ancestors) and indigenous people in Near Oceania (Papuan-related ancestors). Methods: In this study local ancestry was estimated across the genome in Polynesians (23 Tongan subjects) to find the candidate regions of admixture-enabled selection contributed by Papuan-related ancestors. Results: The mean proportion of Papuan-related ancestry across the Polynesian genome was estimated as 24.6% (SD = 8.63%), and two genomic regions, the extended major histocompatibility complex (xMHC) region on chromosome 6 and the ATP-binding cassette transporter sub-family C member 11 (ABCC11) gene on chromosome 16, showed proportions of Papuan-related ancestry more than 5 SD greater than the mean (> 67.8%). The coalescent simulation under the assumption of selective neutrality suggested that such signals of Papuan-related ancestry enrichment were caused by positive selection after admixture (false discovery rate = 0.045). The ABCC11 harbors a nonsynonymous SNP, rs17822931, which affects apocrine secretory cell function. The approximate Bayesian computation indicated that, in Polynesian ancestors, a strong positive selection (s = 0.0217) acted on the ancestral allele of rs17822931 derived from Papuan-related ancestors. Conclusions: Our results suggest that admixture with Papuan-related ancestors contributed to the rapid local adaptation of Polynesian ancestors. Considering frequent admixture events in human evolution history, the acceleration of local adaptation through admixture should be a common event in humans.

28 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MIMariko Isshiki
Mariko Isshiki
AGAnthony Griffen
Anthony Griffen
PMPaul Meissner
Paul Meissner
PSPaulette Spencer
Paulette Spencer
MCMichael D. Cabana
Michael D. Cabana
SRSrilakshmi M. Raj
Srilakshmi M. Raj
The detection of founder pathogenic variants, those observed in high frequency only in a group of individuals with increased inter-relatedness, can help improve delivery of health care for that community. We identified 16 groups with shared ancestry, based on genomic segments that are shared through identity by descent (IBD), in New York City using the genomic data of 25,366 residents from the All Of Us Research Program and the Mount Sinai Bio Me biobank. From these groups we defined 8 as founder populations, mostly communities currently under-represented in medical genomics research, such as Puerto Rican, Garifuna and Filipino/Pacific Islanders. The enrichment analysis of ClinVar pathogenic or likely pathogenic (P/LP) variants in each group identified 202 of these damaging variants across the 8 founder populations. We confirmed disease-causing variants previously reported to occur at increased frequencies in Ashkenazi Jewish and Puerto Rican genetic ancestry groups, but most of the damaging variants identified have not been previously associated with any such founder populations, and most of these founder populations have not been described to have increased prevalence of the associated rare disease. Twenty-five of 51 variants meeting Tier 2 clinical screening criteria (1/100 carrier frequency within these founder groups) have never previously been reported. We show how population structure studies can provide insights into rare diseases disproportionately affecting under-represented founder populations, delivering a health care benefit but also a potential source of stigmatization of these communities, who should be part of the decision-making about implementation into health care delivery. Author Summary: It is well recognized that genomic studies have been biased towards individuals of European ancestry, and that obtaining medical insights for populations under-represented in medical genomics is crucial to achieve health equity. Here, we use genomic information to identify networks of individuals in New York City who are distinctively related to each other, allowing us to define populations with common genetic ancestry based on genetic similarities rather than by self-reported race or ethnicity. In our study of >25,000 New Yorkers, we identified eight highly-interrelated founder populations, with 202 likely disease-causing variants with increased frequencies in specific founder populations. Many of these population-specific variants are new discoveries, despite their high frequency in founder populations. Studying recent genetic ancestry can help reveal population-specific disease insights that can help with early diagnosis, carrier screening, and opportunities for targeted therapies that all help to reduce health disparities in genomic medicine.

30 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MMMarliette R. Matos
Marliette R. Matos
SGSamuel Ghatan
Samuel Ghatan
SBSean Bankier
Sean Bankier
TTTaylor V. Thompson
Taylor V. Thompson
KLKassidy Lundy-Perez
Kassidy Lundy-Perez
JGJohn M. Greally
John M. Greally
Functional interpretation is essential for understanding how genetic variants contribute to complex traits. Here, we identified and characterized regulatory variants in CD4+ T cells collected from 362 donors. We integrated molecular QTL mapping from single-cell RNA-seq profiles and chromatin accessibility with predicted variant effects from a deep learning model trained on chromatin accessibility data. We identified molecular features and transcription factor binding mechanisms underlying variant sharing and mediated effects across the modalities and approaches. While predicted variant effects correlated with molQTLs, only a small fraction of empirically detected molQTLs were discovered by predictive models. MolQTLs, primarily those affecting chromatin, indicated potential molecular drivers for 33% of immune-related GWAS loci, with the deep learning approach providing insights into 4.7% of GWAS loci. These results highlight the value of multi-omic data and systematic integration of empirical and predictive approaches to interpret regulatory effects of genetic variants.

22 July 2025 in Pediatric Pulmonology
Verified
Journal Article
Closed access
DYDavid Yang
David Yang
AGAnthony Griffen
Anthony Griffen
MIMariko Isshiki
Mariko Isshiki
JGJohn M. Greally
John M. Greally
DRDeepa Rastogi
Deepa Rastogi
SRSrilakshmi M. Raj
Srilakshmi M. Raj